Clinical Trials Logo

Clinical Trial Summary

The purpose of this study is to determine whether proactive use of 0.1% tacrolimus ointment once or twice weekly can keep adult facial SD in remission and reduce the incidence of exacerbation.


Clinical Trial Description

Seborrhoeic dermatitis (SD) is a common chronic papulosquamous dermatosis, affecting 2% to 10% of the adult population, mainly those between the ages of 20 and 50 years with a male bias. The affected skin appears erythematous and oedematous, covered with yellow-brown scales, and is often accompanied by pruritus. It typically affects areas containing sebaceous glands, particularly the scalp, ears, face, chest, and intertriginous areas. SD has a chronic course, and relapse is common. Therefore, therapy is directed toward reducing the symptoms or aggravating factors of SD, such as loosening and removal of scales and crusts, inhibition of yeast colonization, control of secondary infection, and reduction of erythema and pruritus. Standard topical treatments for SD include corticosteroids and anti-mycotic medications. However, the chronic use of topical corticosteroids particularly on the face could result in undesirable outcomes, such as telangiectasia, atrophy, striae, peri-oral dermatitis, or tachyphylaxis, and early relapse after discontinuation of treatment. SD relapse prevention strategies have not yet been established, so the investigators suspected that intermittent use of tacrolimus ointment can be effective in preventing SD relapse. ;


Study Design

Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment


Related Conditions & MeSH terms


NCT number NCT01591070
Study type Interventional
Source Pusan National University Hospital
Contact
Status Completed
Phase Phase 4
Start date November 2010
Completion date May 2011

See also
  Status Clinical Trial Phase
Completed NCT01703793 - Safety and Efficacy Study in Subjects With Seborrheic Dermatitis Phase 2
Completed NCT01203189 - Seborrheic Dermatitis: Ketoconazole 2% Foam Versus Ketoconazole 2% Shampoo N/A
Completed NCT00991198 - The Role of Topically Dissolved Oxygen (TDO) to Ameliorate Signs of Photodamage Phase 2
Completed NCT03567980 - A Proof of Concept Clinical Trial Evaluating the Safety and Efficacy of Eucrisa (Crisaborole) in Patients With Seborrheic Dermatitis Phase 4
Recruiting NCT03688971 - Omiganan Twice a Day (BID) in Patients With Facial Seborrheic Dermatitis Phase 2
Recruiting NCT01139749 - Efficacy and Safety of Low-dose Oral Isotretinoin for Seborrhea Phase 4
Completed NCT05105139 - Study to Evaluate the Safety of Sebryl® and Sebryl Plus® in Seborrheic Dermatitis and Psoriasis of Scalp
Completed NCT05787860 - Ruxolitinib in Seborrheic Dermatitis Phase 2
Completed NCT00403559 - A 4 Week Study of Elidel (Pimecrolimus) for the Treatment of Seborrheic Dermatitis Phase 2
Not yet recruiting NCT00767546 - Botulinum Toxin for Treatment of Seborrhic Dermatitis in Parkinsonian Patients Phase 1
Terminated NCT01315951 - Petrolatum's Effect on Initial Symptoms of Nonscalp Seborrheic Dermatitis and Preventing Exacerbation N/A
Recruiting NCT05942248 - The Use of Image-Based Computer Gradings in the Analysis of Acne, Rosacea, Melasma, and Seborrheic Dermatitis N/A
Recruiting NCT06013371 - PDE4 Inhibition in Seborrheic Dermatitis and Papulopustular Rosacea Phase 2
Recruiting NCT05319444 - Cleansing Device for the Treatment of Scalp and Hair Conditions N/A
Completed NCT04445987 - Long-Term Safety of ARQ-154 Foam in Subjects With Seborrheic Dermatitis Phase 2
Completed NCT04973228 - Trial of PDE4 Inhibition With Roflumilast (ARQ-154) Foam 0.3% for the Management of Seborrheic Dermatitis (STRATUM) Phase 3
Completed NCT03114111 - Pilot Study for the Use of Photodynamic Therapy in the Treatment of Seborrheic Dermatitis Early Phase 1
Completed NCT02656368 - Safety and Efficacy of SEBORRHEAMEDIS Face Cream in Patients With Seborrheic Dermatitis N/A
Completed NCT00830908 - HairMax LaserComb Open Label Study to Treat Seborrheic Dermatitis N/A
Completed NCT02349854 - Neurobiology of the Scalp in Seborrheic Dermatitis N/A